WASHINGTON, June 16, 2015 /PRNewswire-USNewswire/ -- The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced the election of five of its newest members to its Board of Directors.
"Over the past couple of months, we have been pleased to welcome five exceptional leaders to PhRMA's Board," said John J. Castellani, PhRMA president and chief executive officer. "Our organization will benefit not only from their deep understanding of the economic, regulatory and legislative issues facing our industry, but also from the global perspective, tested leadership and proven industry success they will bring to bear to help guide PhRMA's work in the coming years."
PhRMA's newest board members include:
Werner Baumann, chairman, Board of Management, Bayer HealthCare AG
Werner Baumann is chairman of the Board of Management of Bayer HealthCare AG. He also serves as chief strategy and portfolio officer of Bayer AG, with responsibility for corporate development and mergers and acquisitions. Previously, Baumann served as Bayer AG's chief financial officer. He has been with the company since 1988, first working in Germany and Spain before assuming leadership roles in the United States and once again in Germany.
Giovanni Caforio, M.D., chief executive officer, Bristol-Myers Squibb
Giovanni Caforio, M.D., is chief executive officer of Bristol-Myers Squibb. Caforio joined the company in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president of the U.S. business in 2011. Prior to becoming CEO, he served as chief operating officer leading a fully integrated worldwide commercial organization and the company-wide functions of Enterprise Services and Global Manufacturing & Supply, and was elected to Bristol-Myers Squibb's Board of Directors in 2014.
Peter Greenleaf, chief executive officer, Sucampo Pharmaceuticals, Inc.
Peter Greenleaf is chief executive officer of Sucampo Pharmaceuticals, Inc., and a member of the company's board of directors. Before joining Sucampo, Greenleaf was CEO and a board member of Histogenics Corporation, a regenerative medicine company, from June 2013 through February 2014. From 2008 to June 2013, Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as president and was responsible for driving the expansion of the company's pipeline and pre-clinical programs and the commercialization of its marketed products. Mr. Greenleaf was also president of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, and the company's previous chief commercial officer.
Ramona Sequeira, president, Takeda Pharmaceuticals U.S.A., Inc.
Ramona Sequeira is president of Takeda Pharmaceutical USA, Inc., responsible for the company's commercial operations in the United States. Prior to joining Takeda, Sequeira held leadership positions at Eli Lilly and Company, both in the United States and United Kingdom. In her role as general manager, Sequeira had responsibility for all affiliate operations in United Kingdom, Republic of Ireland and Northern Europe, and represented the company as a Board member of the Association of the British Pharmaceutical Industry.
Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc
Timothy P. Walbert serves as chairman, president and chief executive officer of Horizon Pharma plc. Before joining the company, Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biopharmaceutical company that was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, he served as executive vice president, Commercial Operations at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Walbert served as divisional vice president and general manager, Immunology, at Abbott Laboratories, now AbbVie, where he led the global development and launch of a multi-indication biologic.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.
Connect with PhRMA
For information on how innovative medicines save lives, please visit: